As a leader in health and agriculture, something is always happening at Bayer in the U.S. and in the countless communities we serve. Take a look below—and check back often—to explore some of our most exciting news and stories as they emerge.
Area
Topic
SearchYour SelectionClear All
Your Selection
Clear All
Latest News
Bayer starts Phase IIa study for treatment of patients with Alport Syndrome
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
Company continues to advance multi-pronged strategy to significantly contain the litigation by the end of 2026
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
U.S. Media Contacts

These contacts are for media inquiries only.
All other inquiries can be directed to:
Bayer Corporation
100 Bayer Boulevard
Whippany, NJ 07981
Phone: 862-404-3000
Click here for general inquiries.
Click here to report an adverse event.
Click here if you are a US healthcare professional seeking medical information.

 

General U.S. Media Inquiries
USmediainquiries@bayer.com

Click here for Global Media Inquiries

Nicole Hayes Headshot

Nicole Hayes  

Director, U.S. Communications
201-421-5268
Nicole.Hayes@bayer.com

Brian Leake Headshot

Brian Leake


Director, External Communications
314-370.3285
brian.leake@bayer.com

Kyel Richard Headshot

Kyel Richard


Deputy Director, External Communications
573-356-0241
kyel.richard@bayer.com

Sue Ann Pentecost Headshot

Sue Ann Pentecost


U.S. Communications
910-221-6446
Sueann.pentecost@bayer.com

Statements

 

Statement on RoundUp Active Ingredient Safety

American Agriculture at Risk- An Open Letter on Glyphosate

Bayer statement on Monsanto/glyphosate trial

Bayer statement on Xarelto March 25, 2019

Kogenate FS Recall Healthcare Provider Notification

Kogenate FS Recall Update

Kogenate FS Recall Bayer Response to NHF/HFA

 

Statement on Delaware Supreme Court’s Decision (Nov. 2023)

“Bayer is pleased with the Delaware Supreme Court’s decision to affirm the Chancery Court’s dismissal with prejudice of Merck’s meritless case against the company. The Supreme Court’s affirmance is based on the same reasons given by the Chancery Court, which found that Merck was solely liable and responsible for all product-liability claims relating to the time before the closing of the Purchase Agreement between the two companies under its terms.”